ANDAs Showing Steady Improvement In First-Cycle Approval Times
First-cycle approvals took longer than multi-cycle approvals in the generic drug user fee program's first year, but decreased dramatically in year two.
You may also be interested in...
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.